Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
GHRP-2
Growth Hormone Releasing Peptide-2, Pralmorelin
Hexarelin
Examorelin, His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2
A synthetic hexapeptide growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Considered one of the most potent GHRPs available, producing stronger GH pulses than GHRP-6 but with more appetite stimulation than ipamorelin. Widely used in anti-aging and performance contexts.
A synthetic hexapeptide growth hormone secretagogue and one of the most potent GH-releasing peptides known. Stimulates GH release more strongly than most other GHS peptides, but also has significant effects on cortisol and prolactin.
Binds to the growth hormone secretagogue receptor (GHS-R1a / ghrelin receptor) in the anterior pituitary, triggering GH release. Also stimulates appetite through hypothalamic ghrelin pathways. Produces a robust GH pulse that synergizes with GHRH analogs like CJC-1295 or sermorelin.
Binds to ghrelin receptors (GHS-R1a) in the pituitary and hypothalamus, triggering strong GH release. Also has direct cardioprotective effects independent of GH, including protection against ischemia-reperfusion injury. Activates the CD36 receptor in cardiac tissue.
- Growth hormone optimization
- Muscle growth and recovery
- Anti-aging protocols
- Improved sleep quality
- Fat loss (via elevated GH)
- Growth hormone optimization
- Muscle mass and strength
- Fat loss
- Cardiac protection (emerging research)
- Recovery from injury
- Increased appetite and hunger
- Water retention
- Elevated cortisol and prolactin (dose-dependent)
- Tingling or numbness at injection site
- Potential blood sugar effects
- Significant cortisol and prolactin elevation (more than Ipamorelin)
- Water retention
- Increased appetite
- Desensitization with prolonged use
- Limited long-term human safety data
Not FDA-approved. Available as a research chemical. Pralmorelin (the INN name) has been studied clinically in Japan for GH deficiency diagnosis but has no approved therapeutic indication in the US.
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.